Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-< 12 years)

Pearlman David S.; Eckerwall Goran; McLaren Julie; Lamarca Rosa; Puu Margareta; Gilbert Ileen; Jorup Carin; Sandin Kristina; Lanz Miguel J.

首页> 外文期刊>Annals of allergy, asthma, and immunology >Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-< 12 years)

【24h】

Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-< 12 years)

机译：哮喘儿童（6- <12岁）的疗效和甲板蛋白质PMDI与蛋白质PMDI的疗效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler (pMDI) have been demonstrated in patients with asthma at least 12 years old.

机译：背景：在哮喘至少12岁的患者中，已对哮喘患者证明了预蒙诺德/福莫特罗加压计量计量剂量吸入器（PMDI）的疗效和安全性。

著录项

来源
《Annals of allergy, asthma, and immunology》 |2017年第4期|共12页
作者
Pearlman David S.; Eckerwall Goran; McLaren Julie; Lamarca Rosa; Puu Margareta; Gilbert Ileen; Jorup Carin; Sandin Kristina; Lanz Miguel J.;
展开▼
作者单位

Colorado Allergy &

Asthma Ctr PC 125 Rampart Way Suite 150 Denver CO 80230 USA;

AstraZeneca R&

D Gothenburg Sweden;

AstraZeneca Gaithersburg MD USA;

AstraZeneca Barcelona Spain;

AstraZeneca R&

D Gothenburg Sweden;

AstraZeneca Wilmington DE USA;

AstraZeneca R&

D Gothenburg Sweden;

AstraZeneca R&

D Gothenburg Sweden;

AAADRS Clin Res Ctr Allergy Asthma &

Immunol Coral Gables FL USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-< 12 years) [J] . Pearlman David S., Eckerwall Goran, McLaren Julie, Annals of allergy, asthma, and immunology . 2017,第4期

机译：哮喘儿童（6- <12岁）的疗效和甲板蛋白质PMDI与蛋白质PMDI的疗效和安全性
2. SAFETY OF BUDESONIDE/FORMOTEROL PRESSURIZED METERED-DOSE INHALER VERSUS BUDESONIDE IN CHILDREN (6-< 12 YEARS) WITH ASTHMA [J] . Lanz M., Eckerwall G., McLaren J., Annals of allergy, asthma, and immunology . 2016,第5Suppla1期

机译：哮喘患者（6岁以下<12岁）中布地奈德/甲酚密米特吸入剂对布地奈德的安全性
3. Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial [J] . Akash Balki, S. Balamurugan, Suhas Bardapurkar, Pulmonary pharmacology & therapeutics . 2018,第期

机译：氟酮/福莫特酚与预升至严重持久性哮喘的成年人（Acthiss）的氟酮/蛋白质醇的比较：12周随机对照试验的结果
4. Simultaneously Running Two LC-MS/MS Methods for Determining Formoterol and Budesonide in Human Plasma with a Dual HPLC System [C] . Xinping Fang, Lailiang Zhai, Dawei Zhou American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：同时运行两种LC-MS / MS方法，用于用双HPLC系统在人血浆中测定霉菌和蛋白质蛋白酶
5. Lung delivery of budesonide and its efficacy in a tumor model [D] . Bandi, Nagesh. 2003

机译：布地奈德的肺递送及其在肿瘤模型中的功效
6. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma [O] . A H Morice, S Peterson, O Beckman, -1

机译：新型布地奈德/福莫特罗pMDI与布地奈德pMDI和布地奈德/福莫特罗DPI在哮喘中的治疗比较
7. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6–<12 years) [O] . David S. Pearlman, Göran Eckerwall, Julie McLaren, 2017

机译：哮喘儿童（6- <12岁）的疗效/甲酚PMDI对蛋白质/ Formoterol PMDI的疗效和安全性

Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-< 12 years)

摘要

著录项

相似文献

相关主题

期刊订阅